Publications by authors named "Pavania Elavalakanar"
Background: Venous thromboembolism (VTE) is a leading cause of preventable mortality among hospitalized patients, but appropriate risk assessment and thromboprophylaxis remain underutilized or misapplied.
Objectives: We conducted an electronic survey of US health care providers to explore attitudes, practices, and barriers related to thromboprophylaxis in adult hospitalized patients and at discharge.
Results: A total of 607 US respondents completed the survey: 63.
Article Synopsis
- The study examined whether having low platelet counts (thrombocytopenia) increases the risk of bleeding in patients with atrial fibrillation (AF) on anticoagulants, comparing two groups: those with low platelets (<100,000/μL) and those with normal counts (>150,000/μL).
- Results showed that patients with AF and thrombocytopenia had significantly higher rates of major bleeding (13.3% vs 5.7%) and clinically relevant bleeding (24.5% vs 16.7%) after one year.
- Thrombocytopenia was confirmed as an independent risk factor for major bleeding, with the risk increasing as the severity of low platelet counts worsened, highlighting
Steroid-refractory chronic graft-versus-host disease (cGVHD) after allogeneic transplant remains a significant cause of morbidity and mortality. Abatacept is a selective costimulation modulator, used for the treatment of rheumatologic diseases, and was recently the first drug to be approved by the US Food and Drug Administration for the prophylaxis of acute graft-versus-host disease. We conducted a phase 2 study to evaluate the efficacy of abatacept in steroid-refractory cGVHD.
View Article and Find Full Text PDFBackground: Spontaneous intracranial hemorrhage (ICH) is a frequent and severe consequence of primary brain tumors. The safety of antiplatelet medications in this patient population is undefined.
Objective: The primary objective was to determine whether antiplatelet medications are associated with an increased risk of ICH in patients with primary brain tumors.
Article Synopsis
- CD19 is a common target for therapies in treating B-cell malignancies, particularly in DLBCL, with CAR T-cell therapy showing improved patient outcomes but facing limitations.
- Other drug types like monoclonal antibodies and bispecific T-cell engagers are also effective against CD19, but the best ways to select and sequence treatments are still unclear.
- The review analyzes key clinical trials for therapies like tafasitamab, loncastuximab tesirine, and blinatumomab, highlighting their strengths and weaknesses, as well as the potential for reusing anti-CD19 therapies after patients relapse post-CAR T-cell treatment.
Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951).
View Article and Find Full Text PDFArticle Synopsis
- * A survey of 189 oncology trainees revealed that while over half discussed cannabis with multiple patients, only 13% felt knowledgeable enough to make recommendations about its use.
- * Trainees who had received formal training on medical cannabis were more likely to engage in discussions with patients and feel informed about its recommendations, highlighting a gap in oncology education regarding this topic.
COVID-19 (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) is associated with coagulopathy through numerous mechanisms. The reported incidence of venous thromboembolism (VTE) in hospitalized patients with COVID-19 has varied widely, and several meta-analyses have been performed to assess the overall prevalence of VTE. The novelty of this coronavirus strain along with its unique mechanisms for microvascular and macrovascular thrombosis has led to uncertainty as to how to diagnose, prevent, and treat thrombosis in patients affected by this virus.
View Article and Find Full Text PDFAlthough intracranial hemorrhage (ICH) is frequent in the setting of brain metastases, there are limited data on the influence of antiplatelet agents on the development of brain tumor-associated ICH. To evaluate whether the administration of antiplatelet agents increases the risk of ICH, we performed a matched cohort analysis of patients with metastatic brain tumors with blinded radiology review. The study population included 392 patients with metastatic brain tumors (134 received antiplatelet agents and 258 acted as controls).
View Article and Find Full Text PDF